Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

@article{Prospero2007NeurologicalEO,
  title={Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial},
  author={N. D. Prospero and A. Baker and N. Jeffries and K. Fischbeck},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={878-886}
}
  • N. D. Prospero, A. Baker, +1 author K. Fischbeck
  • Published 2007
  • Medicine
  • The Lancet Neurology
  • BACKGROUND Friedreich's ataxia (FA) is a progressive, multisystem, degenerative disorder caused by a reduction in frataxin. Loss of frataxin results in mitochondrial dysfunction and oxidative damage in patients and model systems. Previous studies have indicated that the antioxidant idebenone (5 mg/kg daily) reduces cardiac hypertrophy, but definite improvement in neurological function has not been shown. METHODS 48 genetically confirmed FA patients, aged 9-17 years, were enrolled in a 6-month… CONTINUE READING
    252 Citations
    Idebenone in Friedreich's ataxia
    • 11
    • Highly Influenced
    IGF-1 in Friedreich’s Ataxia – proof-of-concept trial
    • 10
    • PDF
    Clinical experience with high-dose idebenone in Friedreich ataxia
    • 50
    Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.
    • 29
    A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
    • 146
    • Highly Influenced
    • PDF
    A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial
    • 61
    • PDF

    References

    SHOWING 1-10 OF 25 REFERENCES
    Friedreich's ataxia: idebenone treatment in early stage patients.
    • 102
    Oxidative stress in patients with Friedreich ataxia
    • 287
    Idebenone treatment in Friedreich’s ataxia
    • 151